RARE vs. BHVN, SMMT, PBH, IDYA, AXSM, HCM, XENE, INSM, CRNX, and CORT
Should you be buying Ultragenyx Pharmaceutical stock or one of its competitors? The main competitors of Ultragenyx Pharmaceutical include Biohaven (BHVN), Summit Therapeutics (SMMT), Prestige Consumer Healthcare (PBH), IDEAYA Biosciences (IDYA), Axsome Therapeutics (AXSM), HUTCHMED (HCM), Xenon Pharmaceuticals (XENE), Insmed (INSM), Crinetics Pharmaceuticals (CRNX), and Corcept Therapeutics (CORT). These companies are all part of the "pharmaceutical preparations" industry.
Biohaven (NYSE:BHVN) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, community ranking, dividends and earnings.
Biohaven has a net margin of 0.00% compared to Biohaven's net margin of -138.58%. Ultragenyx Pharmaceutical's return on equity of -147.06% beat Biohaven's return on equity.
Biohaven currently has a consensus price target of $51.63, suggesting a potential upside of 38.15%. Ultragenyx Pharmaceutical has a consensus price target of $87.85, suggesting a potential upside of 109.81%. Given Biohaven's higher possible upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Biohaven.
88.8% of Biohaven shares are owned by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 16.0% of Biohaven shares are owned by company insiders. Comparatively, 6.8% of Ultragenyx Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Biohaven has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500.
Biohaven has higher revenue and earnings than Ultragenyx Pharmaceutical. Biohaven is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Ultragenyx Pharmaceutical received 434 more outperform votes than Biohaven when rated by MarketBeat users. Likewise, 77.11% of users gave Ultragenyx Pharmaceutical an outperform vote while only 65.43% of users gave Biohaven an outperform vote.
In the previous week, Biohaven had 24 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 26 mentions for Biohaven and 2 mentions for Ultragenyx Pharmaceutical. Biohaven's average media sentiment score of 0.62 beat Ultragenyx Pharmaceutical's score of 0.44 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.
Summary
Biohaven and Ultragenyx Pharmaceutical tied by winning 9 of the 18 factors compared between the two stocks.
Get Ultragenyx Pharmaceutical News Delivered to You Automatically
Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ultragenyx Pharmaceutical Competitors List
Related Companies and Tools
